Crescent Biopharma (CBIO) Other Operating Expenses (2024 - 2025)

Crescent Biopharma (CBIO) reported Other Operating Expenses of $16.8 million for Q4 2025, up 1273.69% quarter-over-quarter from $1.2 million in Q3 2024.

Crescent Biopharma (CBIO) Other Operating Expenses (2024 - 2025) Analysis & Trends

Crescent Biopharma (CBIO) has 2 years of Other Operating Expenses data on file, last reported at $16.8 million in Q4 2025.

  • Other Operating Expenses for Q4 2025 came in at $16.8 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $16.8 million (up 1273.69% YoY), and the FY2024 annual result was $1.2 million, changed N/A from the prior year.
  • Other Operating Expenses improved to $16.8 million in Q4 2025 per CBIO's latest filing, from $1.2 million in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $16.8 million in Q4 2025 and troughed at $1.2 million in Q3 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn -
7 Psyence Biomedical 212.16 Bn 212.16 Bn -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn
9 Abivax 91.96 Bn 91.96 Bn -
10 Crescent Biopharma 486.92 Mn 297.76 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2025 16.83 Mn
Sep 30, 2024 1.22 Mn